Targeting the HGF/c-Met pathway, especially using rilotumumab, impacts angiogenesis as evidenced by a decrease in the proliferation of endothelial cells and tube formation in pancreatic cancer [38] and glioma [39]. This evidence concerns the gene MET and pancreatic neoplasm.